Caramelo C, Fernández-Gallardo S, Santos J C, Iñarrea P, Sánchez-Crespo M, López-Novoa J M, Hernando L
Eur J Clin Invest. 1987 Feb;17(1):7-11. doi: 10.1111/j.1365-2362.1987.tb01218.x.
The levels of platelet-activating factor (paf-acether) were measured in blood and ascitic fluid from cirrhotic patients and in blood from a group of controls, using a recently described technique for extraction and measurement. In addition, activity of acetylhydrolase, the main catabolic enzyme for paf-acether, was also measured. The highest levels of paf-acether in blood were found in decompensated cirrhotics (1.78 +/- 0.62 ng ml-1; mean +/- SD, n = 8). Compensated cirrhotics showed lower blood values (0.79 +/- 0.21, n = 4), but higher than controls (0.20 +/- 0.04, n = 12). Paf-acether levels in ascitic fluid were similar to those of blood. Values of acetylhydrolase in serum were similar in all the groups studied (3.0 +/- 0.4 in cirrhotics vs. 2.3 +/- 0.4 nmol min-1 mg-1 of protein in controls). These data suggest an enhanced production of paf-acether in cirrhotic patients rather than a decreased catabolism. High levels of paf-acether in blood could be involved in the impaired haemodynamics of cirrhotic patients and in their renal function alterations.
采用最近描述的提取和测量技术，对肝硬化患者血液和腹水以及一组对照者血液中的血小板活化因子（PAF - 乙酰醚）水平进行了测定。此外，还测定了PAF - 乙酰醚的主要分解代谢酶乙酰水解酶的活性。失代偿期肝硬化患者血液中PAF - 乙酰醚水平最高（1.78±0.62 ng/ml；平均值±标准差，n = 8）。代偿期肝硬化患者血液中PAF - 乙酰醚水平较低（0.79±0.21，n = 4），但高于对照组（0.20±0.04，n = 12）。腹水中PAF - 乙酰醚水平与血液相似。在所研究的所有组中，血清中乙酰水解酶的值相似（肝硬化患者为3.0±0.4，对照组为2.3±0.4 nmol·min⁻¹·mg⁻¹蛋白质）。这些数据表明肝硬化患者PAF - 乙酰醚生成增加而非分解代谢减少。血液中高水平的PAF - 乙酰醚可能与肝硬化患者血流动力学受损及其肾功能改变有关。
